PROCEPT BioRobotics Will Report Earnings November 4
The San Jose surgical robotics company will release its third quarter 2026 financial results after market close.
Updated on Oct. 12, 2026 in Public Companies
Live Poll
Do you generally trust the quarterly financial reports issued by medical technology companies?
PROCEPT BioRobotics Corporation is set to report its third quarter 2026 financial results on November 4, 2026. The firm, headquartered in San Jose, will follow the report with a live conference call.
Why it matters
The disclosure will provide investors with an update on the commercial adoption of the company's urology-focused robotic surgical platforms. The results offer insight into the scaling of Aquablation therapy for the treatment of benign prostatic hyperplasia.
PROCEPT BioRobotics supports its Aquablation therapy with approximately 250 peer-reviewed publications. The company manufactures the AQUABEAM and HYDROS Robotic Systems for urological surgery.
The players
PROCEPT BioRobotics Corporation
This is a surgical robotics company based in San Jose that specializes in urological procedures and technology.
The details
Investors can participate in the discussion by accessing a webcast available on the company's official website following the market close on November 4. The presentation will detail the latest operational progress regarding their specialized surgical robotics technology.
Timeline
October 12, 2026: The company announced its third quarter earnings date.
November 4, 2026: Financial results will be reported after market close.
November 4, 2026: The conference call will begin at 4:30 p.m. Eastern Time.
Market Landscape
The firm competes within the specialized field of robotic urology, seeking to gain market share against established surgical standards. This update illustrates the company's trajectory as it integrates advanced hardware into the broader clinical landscape.
The upcoming financial report will demonstrate how the company is scaling its presence in the U.S. market, where benign prostatic hyperplasia affects 40 million men. Current and potential shareholders will gain transparency into the firm's growth strategy and future operational capacity.
The takeaway
The quarterly report serves as a benchmark for the firm's ability to maintain its growth trajectory in the competitive surgical robotics sector. Stakeholders should monitor the call for updates on clinical data that may influence future adoption rates of their robotic systems.
What happens next
A replay of the November 4 conference call webcast will be available on the company website for at least 90 days following the event.
Further reading
For more on the financial performance of area firms, visit Public Companies.
More information
Investors can view official documents and webcast details via the investor relations web portal.
Live Poll
Do you generally trust the quarterly financial reports issued by medical technology companies?
